| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Introduction: Severe forms of psoriasis, where traditional topical therapy fails, are indicated for systemic treatment with conventional and biological medicinal products. The conventional systemic therapy includes phototherapy and treatment with methotrexate, cyclosporin and acitretin. Currently used biological preparations include inhibitors of TNF-alpha (etanercept, adalimumab, infliximab) and monoclonal antibody ustekinumab. We are presenting our own more than five-year experience with systemic treatment of severe forms of psoriasis. Methods: A total of 66 patients treated with systemic therapy (except for phototherapy) were divided into groups based on provided therapy. Therapeutic doses were administered according to the recommendations of the manufacturer and dermatological societies. Standard PASI and BSA indices were used to evaluate clinical condition at weeks 0, 12 and 24. Collected data were statistically evaluated using SPSS software version 15 (SPSS Inc.; Chicago, USA) at the probability level of 0.05. Results: In many cases, differences in the decrease of PASI score and BSA index between individual groups of patients treated with different preparations were statistically significant at monitored intervals. At week 12, comparison of PASI score showed a decrease by 75% or more in a significantly higher number of patients treated with infliximab + methotrexate when compared to those treated with acitretin. At week 24, identical comparison showed a significantly higher number of patients in the group treated with etanercept or adalimumab when compared to the group receiving methotrexate. Conclusion: Systemic therapy provides a significant benefit to patients with severe psoriasis. Biological preparations are more effective when compared to conventional medications. Conventional therapy is often limited by serious side effects and is generally less tolerated than biological treatment.
- Introduction: Severe forms of psoriasis, where traditional topical therapy fails, are indicated for systemic treatment with conventional and biological medicinal products. The conventional systemic therapy includes phototherapy and treatment with methotrexate, cyclosporin and acitretin. Currently used biological preparations include inhibitors of TNF-alpha (etanercept, adalimumab, infliximab) and monoclonal antibody ustekinumab. We are presenting our own more than five-year experience with systemic treatment of severe forms of psoriasis. Methods: A total of 66 patients treated with systemic therapy (except for phototherapy) were divided into groups based on provided therapy. Therapeutic doses were administered according to the recommendations of the manufacturer and dermatological societies. Standard PASI and BSA indices were used to evaluate clinical condition at weeks 0, 12 and 24. Collected data were statistically evaluated using SPSS software version 15 (SPSS Inc.; Chicago, USA) at the probability level of 0.05. Results: In many cases, differences in the decrease of PASI score and BSA index between individual groups of patients treated with different preparations were statistically significant at monitored intervals. At week 12, comparison of PASI score showed a decrease by 75% or more in a significantly higher number of patients treated with infliximab + methotrexate when compared to those treated with acitretin. At week 24, identical comparison showed a significantly higher number of patients in the group treated with etanercept or adalimumab when compared to the group receiving methotrexate. Conclusion: Systemic therapy provides a significant benefit to patients with severe psoriasis. Biological preparations are more effective when compared to conventional medications. Conventional therapy is often limited by serious side effects and is generally less tolerated than biological treatment. (en)
|
| Title
| - Experience with the systemic treatment of severe forms of psoriasis
- Experience with the systemic treatment of severe forms of psoriasis (en)
|
| skos:prefLabel
| - Experience with the systemic treatment of severe forms of psoriasis
- Experience with the systemic treatment of severe forms of psoriasis (en)
|
| skos:notation
| - RIV/61989592:15110/12:33138512!RIV13-MSM-15110___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/12:33138512
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - ustekinumab; infliximab; etanercept; adalimumab; biological therapy; conventional therapy; systemic therapy; psoriasis (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - Biomedical Papers-Olomouc
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Zapletalová, Jana
- Tichý, Martin
|
| http://linked.open...ain/vavai/riv/wos
| |
| issn
| |
| number of pages
| |
| http://bibframe.org/vocab/doi
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)